Bonjour,
We're having a lot of fun at Boys Club these days. The content machine is being guided by our varied interests, edgelording prowess, and an insatiable curiosity. Follow us on IG to catch it all.
This week Meta invited me to a very intimate live recording of an interview with Mark Zuckerberg to talk about the Meta AI glasses. I wrote about it on X and people got UPSET (j'adore and désolé).
ily,
advertisement
The fifth episode of Show Me Your Stack presented by Vercel is out NOW! This week we went full slop-free zone with Charlie Holtz. Watch now!
This show is brought to you by Vercel, the agentic infrastructure company, who have been making it easier and faster to build since day one. Their application builder v0 takes ideas to deployed product in minutes.
This week a conspiracy theory that has some legs hit the timeline in a major way.
On Tuesday, STAT News broke a story that Eli Lilly, the pharmaceutical company behind the GLP-3 drug Retatrutide, got approval to run something called a 'compassionate use' program for a single patient.
A few things to level set on here before we go further.
First, an ELI5 on Retatrutide. We've all heard of Ozempic, which is a GLP-1 that mimics one hormone. What makes Reta different, and why people in certain corners of the internet (looksmaxxers and biohackers) are calling it a miracle drug, is that it hits three receptors instead of one: GLP-1, GIP, and glucagon. That's why some people call it a GLP-3, even though GLP-3 isn't technically a real hormone.
It's in phase three trials, still not FDA-approved, but expected to get the green light sometime in 2027. I've been microdosing Reta for the last three months with results I'm very happy with. If you want to hear about my personal experience, feel free to reply to this email. I'm happy to chat, will literally never sell you it, and am a world-class oversharer. And if you do not want to hear about my experience, no worries!
PSA: do this shit at your own risk and do not take this newsletter as medical advice.
Now, onto 'Compassionate use.' Ordinarily these programs are designed to give experimental treatments to large cohorts of patients with a life-threatening condition. In this case, STAT News reported it was approved for one 79-year-old man who started using it in April.
As you can imagine, Twitter went off speculating that this man is Donald J. Trump, while others said ain’t no way.
The other major chatter on the timeline was about $LLY ( ▲ 1.93% ), Eli Lilly's ticker.
The argument people are making is that it's in an interesting window right now: the phase three data is blowing people away, but it's not FDA-approved yet, and that gap is an opportunity for retail investors. Also not financial advice, but the stock is up almost 7% today.
Which seems to be my lucky number, because earlier this week I wrote an X article about how the pervasive use of GLPs in the US (1 in 8 Americans are on one) is completely restructuring hot girl markets, looking at Revolve Group ($RVLV ( ▲ 4.24% )) as an example of this. The next day the stock pumped 7% (holy number).
Anyway, this month on Too Online we'll be covering Hot Girl Summer and the drugs, tech, and trends that move the market. Forward this to that one friend (you know who they are) to subscribe here.
